Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Emma Materne, Hyon Choi, Baijun Zhou, Karen H Costenbader, Yuqing Zhang, April Jorge
OBJECTIVE: We investigated the comparative risk of infection with belimumab versus oral immunosuppressants for the treatment of systemic lupus erythematosus (SLE). METHODS: Using observational data from a U.S. multi-center electronic health record database, we identified patients with SLE but without lupus nephritis who initiated belimumab, azathioprine, methotrexate, or mycophenolate between 2011-2021. We designed and emulated hypothetical target trials to estimate the cumulative incidence and hazard ratios (HRs) of serious infection and hospitalization for serious infection comparing belimumab vs...
June 1, 2023: Arthritis & Rheumatology
#2
JOURNAL ARTICLE
Daphne J Theodorou, Stavroula J Theodorou, Niki D Tsifetaki
No abstract text is available yet for this article.
June 1, 2023: Arthritis & Rheumatology
#3
JOURNAL ARTICLE
Kenneth T Gao, Emily Xie, Vincent Chen, Claudia Iriondo, Francesco Calivà, Richard B Souza, Sharmila Majumdar, Valentina Pedoia
OBJECTIVE: While it is established that structural damage of the meniscus is linked to knee osteoarthritis (OA) progression, the predisposition to future development of OA due to geometric meniscal shapes is plausible and unexplored. This study aims to identify common variations in meniscal shape and determine their relationships to tissue morphology, OA onset, and longitudinal changes in cartilage thickness. METHODS: 4,790 participants from the Osteoarthritis Initiative dataset were studied...
June 1, 2023: Arthritis & Rheumatology
#4
LETTER
Julianna Desmarais, James T Rosenbaum, Mark Link, Richard Kovacs
No abstract text is available yet for this article.
May 25, 2023: Arthritis & Rheumatology
#5
LETTER
M Rashedul Hoque, Diane Lacaille, John M Esdaile, Hui Xie, J Antonio Aviña-Zubieta
No abstract text is available yet for this article.
May 25, 2023: Arthritis & Rheumatology
#6
JOURNAL ARTICLE
James Ward, Mythri Ambatipudi, Terrance P O'Hanlon, Michael A Smith, Melissa de Los Reyes, Adam Schiffenbauer, Saifur Rahman, Kamelia Zerrouki, Frederick W Miller, Miguel A Sanjuan, Jian-Liang Li, Kerry A Casey, Lisa G Rider
OBJECTIVE: Transcript and protein expression were interrogated to examine gene locus and pathway regulation in the peripheral blood of active adult dermatomyositis (DM) and juvenile DM (JDM) patients receiving immunosuppressive therapies. METHODS: Expression data from 14 DM and 12 JDM patients were compared to matched healthy controls. Regulatory effects at the transcript and protein level were analyzed by multi-enrichment analysis for assessment of affected pathways within DM and JDM...
May 25, 2023: Arthritis & Rheumatology
#7
JOURNAL ARTICLE
David Simon, Ioanna Minopoulou, Stephan Kemenes, Sara Bayat, Koray Tascilar, Melek Yalcin Mutlu, Larissa Valor-Méndez, Gerhard Krönke, Axel J Hueber, Georg Schett, Arnd Kleyer
OBJECTIVES: Rheumatoid arthritis (RA) is characterized by erosive joint damage, deterioration of bone mass and biomechanics. Preclinical evidence suggests a beneficial effect of Janus Kinase inhibition (JAKi) on bone properties, but clinical data are scarce to date. In this study we evaluated the effect of JAKi through baricitinib (BARI) on (i) volumetric bone mineral density (vBMD), bone microstructure, biomechanics, erosion repair and (ii) synovial inflammation in RA patients. METHODS: Prospective, single-arm, interventional, open-label, single-center phase 4 study in RA patients with pathological bone status and clinical indication of JAKi (BARE BONE trial)...
May 25, 2023: Arthritis & Rheumatology
#8
JOURNAL ARTICLE
Gaetane Nocturne, Xavier Mariette
The management of Sjogren's disease is challenging because of several factors. Indeed, the presentations are heterogeneous, and one must be able to identify prognostic markers to adapt the follow-up. In addition, there is no validated treatment. Nevertheless, international experts have been working for several years to establish recommendations to guide management. However, research in this field is extremely active, and we can hope for the development of effective treatments for our patients in the near future...
May 25, 2023: Arthritis & Rheumatology
#9
JOURNAL ARTICLE
Bryant R England, Benjamin J Smith, Nancy A Baker, Jennifer L Barton, Carol A Oatis, Gordon Guyatt, Allen Anandarajah, Kristine Carandang, Karmela Kim Chan, Deb Constien, Eileen Davidson, Carole V Dodge, Anita Bemis-Dougherty, Sotiria Everett, Nadine Fisher, Liana Fraenkel, Susan M Goodman, Janet Lewis, Victoria Menzies, Larry W Moreland, Iris Navarro-Millan, Sarah Patterson, Lawrence Rick Phillips, Neha Shah, Namrata Singh, Daniel White, Rawan AlHeresh, Kamil E Barbour, Thomas Bye, Dana Guglielmo, Rebecca Haberman, Tate Johnson, Anatole Kleiner, Chris Y Lane, Linda C Li, Hiral Master, Daniel Pinto, Janet L Poole, Kimberly Steinbarger, Daniel Sztubinski, Louise Thoma, Vlad Tsaltskan, Marat Turgunbaev, Courtney Wells, Amy S Turner, Jonathan R Treadwell
OBJECTIVE: To develop initial American College of Rheumatology (ACR) guidelines on the use of exercise, rehabilitation, diet, and additional interventions in conjunction with disease-modifying antirheumatic drugs (DMARDs) as part of an integrative management approach for people with rheumatoid arthritis (RA). METHODS: An interprofessional guideline development group constructed clinically relevant Population, Intervention, Comparator, and Outcome (PICO) questions...
May 25, 2023: Arthritis & Rheumatology
#10
JOURNAL ARTICLE
Torgny Karlsson, Fatemeh Hadizadeh, Mathias Rask-Andersen, Åsa Johansson, Weronica E Ek
OBJECTIVE: While the association between obesity and risk of rheumatic disease is well established, the precise causal relation has not been conclusively proved. Here, we estimate the causal effect of body mass index (BMI) on the risk of developing five different rheumatic diseases. METHODS: Linear and nonlinear mendelian randomization (MR) were used to estimate the effect of BMI on risk of rheumatic disease, and sex-specific effects were identified. Analyses were performed in 361,952 participants from the UK Biobank cohort for the five rheumatic diseases: rheumatoid arthritis (N=8,381 cases), osteoarthritis (N=87,430), psoriatic arthropathy (N=933), gout (N=13,638), and inflammatory spondylitis (N=4,328)...
May 23, 2023: Arthritis & Rheumatology
#11
JOURNAL ARTICLE
Yubin Luo, Yanli Tong, Liang Wu, Haitao Niu, Yanhong Li, Lin Chong Su, Yuxi Wu, Aline Bozec, Mario M Zaiss, Pingying Qing, Hua Zhao, Chunyu Tan, Qiuping Zhang, Yi Zhao, Huairong Tang, Yi Liu
OBJECTIVE: We aimed to decipher the gut microbiome (GM) and serum metabolic characteristic of individuals at high risk for rheumatoid arthritis (RA) and to investigate the causative effect of GM on the mucosal immune system and its involvement in the pathogenesis of arthritis. DESIGN: Fecal samples were collected from 38 healthy individuals (HCs) and 53 high-risk RA individuals with anti-citrullinated protein antibody (ACPA)-positivity (PreRA), 12 of 53 PreRA developed RA within 5 years of follow-up...
May 23, 2023: Arthritis & Rheumatology
#12
JOURNAL ARTICLE
Chenxiang Zheng, Fan Wang, Yue Sun, Zhuochao Zhou, Yijun You, Dongyi He, Xiaoxia Zhu, Lindi Jiang, Cui Lu, Lijun Wu, Hongzhi Wang, Hanying Mei, Ting Zeng, Hui Zheng, Jialing Teng, Honglei Liu, Xiaobing Cheng, Yutong Su, Hui Shi, Qiongyi Hu, Xueming Jian, Aamir Fahira, Qiangzhen Yang, Ke Wang, Yanqin Wen, Zhuo Wang, Jinyan Huang, Chengde Yang, Yongyong Shi, Junna Ye
OBJECTIVE: Previous studies underline the genetic susceptibility in the pathogenesis of Palindromic Rheumatism (PR), but the known PR loci only explain partially the disease's genetic background. We aim to genetically identify PR by whole exome sequencing (WES). METHODS: This multi-center prospective study was conducted in ten Chinese specialized rheumatology centers between September 2015 and January 2020. WES was performed in a PR cohort (185 PR cases and 272 healthy controls)...
May 23, 2023: Arthritis & Rheumatology
#13
REVIEW
Nikita Arumalla, Chun K D Chan, Mark Gibson, Yik L Man, Maryam A Adas, Sam Norton, James B Galloway, Toby Garrood
OBJECTIVE: The inflammatory arthritides (IA) make up a significant proportion of conditions followed-up in rheumatology clinics. These patients require regular monitoring, but this is increasingly difficult with rising patient numbers and demand on clinics. Our objective is to evaluate the clinical impact of electronic Patient Reported Outcome Measures (ePROMs) as a digital remote monitoring intervention on disease activity, treatment decisions and healthcare resource use in patients with IA...
May 19, 2023: Arthritis & Rheumatology
#14
JOURNAL ARTICLE
Philip Mease, Philip Helliwell, Paula Silwinska-Stanczyk, Malgorzata Miakisz, Andrew Ostor, Elena Peeva, Michael S Vincent, Qiankun Sun, Vanja Sikirica, Randall Winnette, Ruolun Qiu, Gang Li, Gang Feng, Jean S Beebe, David A Martin
OBJECTIVE: Brepocitinib is a tyrosine kinase 2/Janus kinase 1 inhibitor in development for treatment of several immunological diseases. Efficacy and safety of oral brepocitinib were assessed in participants with moderately-to-severely active psoriatic arthritis (PsA) for up to 52 weeks. METHODS: This placebo-controlled, dose-ranging, phase IIb study randomized participants to brepocitinib 10 mg once daily (QD), 30 mg QD, 60 mg QD, or placebo, advancing to brepocitinib 30 or 60 mg QD at week 16...
May 17, 2023: Arthritis & Rheumatology
#15
JOURNAL ARTICLE
Léa Debrut, Margherita Giannini, Delphine Klein, Lionel Spielmann, Philippe Mertz, Thierry Martin, Aleksandra Nadaj-Pakleza, Sandrine Hirschi, Benoit Nespola, Béatrice Lannes, Joëlle Terzic, Olivier Hinschberger, Benjamin Dervieux, Dan Lipsker, Laurent Arnaud, Jacques-Eric Gottenberg, Jean François Kleinmann, Bernard Geny, François Séverac, Michel Velten, Jean Sibilia, Alain Meyer
OBJECTIVE: Inflammatory myopathies (IM), characterized by muscle inflammation and weakness, are rare systemic diseases. Our previous study estimated an IM incidence rate of 7.98 cases/million/year (95% CI: [7.38-8.66]) and highlighted important variations that were likely due to methodological issues rather than true epidemiological differences. The aim of this study was to refine the incidence of IM, using the 2017 ACR/EULAR IM classification criteria and a quadruple source capture-recapture method during a 6-year period in Alsace (France), a 2-million-population region, benefiting from good access to healthcare and accredited IM referral centers...
May 16, 2023: Arthritis & Rheumatology
#16
EDITORIAL
Zachary S Wallace, Michael Putman
No abstract text is available yet for this article.
May 16, 2023: Arthritis & Rheumatology
#17
EDITORIAL
Richard F Loeser
No abstract text is available yet for this article.
May 16, 2023: Arthritis & Rheumatology
#18
EDITORIAL
David S Pisetsky
No abstract text is available yet for this article.
May 16, 2023: Arthritis & Rheumatology
#19
JOURNAL ARTICLE
Vijay Joshua, Malena Loberg Haarhaus, Aase Hensvold, Heidi Wähämaa, Christina Gerstner, Monika Hansson, Lena Israelsson, Ragnhild Stålesen, Magnus Sköld, Johan Grunewald, Lars Klareskog, Caroline Grönwall, Bence Réthi, Anca Catrina, Vivianne Malmström
OBJECTIVE: The lung is implicated as a site for breaching tolerance prior to onset of seropositive RA. To substantiate this, we have investigated lung-resident B cells in bronchoalveolar lavage (BAL) samples from early untreated RA patients (n=9) and anti-citrullinated protein antibody (ACPA)-positive individuals at risk of developing RA (n=3). METHODS: Single B cells (n=7680) were phenotyped and isolated from BAL of individuals during the risk-RA phase and at RA diagnosis...
May 16, 2023: Arthritis & Rheumatology
#20
JOURNAL ARTICLE
David R Jayne, Jürgen Steffgen, Juanita Romero-Diaz, Ingeborg Bajema, Dimitrios T Boumpas, Kajohnsak Noppakun, Hirofumi Amano, Harold Michael Gomez, Bancha Satirapoj, Yingyos Avihingsanon, Ratana Chawanasuntorapoj, Magdalena Madero, Beata Naumnik, Rhona Recto, Nora Fagan, Ivette Revollo, Jing Wu, Sudha Visvanathan, Richard Furie
OBJECTIVE: To characterize its dose-response relationship, BI 655064 (an anti-CD40 monoclonal antibody) was tested as add-on to mycophenolate and glucocorticoids in patients with active lupus nephritis (LN). METHODS: 121 patients were randomized (2:1:1:2) to placebo or BI 655064 120mg, 180mg or 240mg and received a weekly loading dose for 3 weeks followed by dosing every 2 weeks for the 120mg and 180mg groups, and 120mg weekly for the 240mg group...
May 16, 2023: Arthritis & Rheumatology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
